Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024)

Spruce Biosciences (SPRB) has disclosed Current Deferred Revenue for 2 consecutive years, with $700000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Current Deferred Revenue fell 91.03% to $700000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $700000.0, a 91.03% decrease, with the full-year FY2023 number at $4.9 million, changed N/A from a year prior.
  • Current Deferred Revenue was $700000.0 for Q3 2024 at Spruce Biosciences, down from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.2 million in Q1 2023 to a low of $700000.0 in Q3 2024.